SSTR1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: SSTR1

NCBI ID: G6751

SSTR1

Other Name(s): Somatostatin receptor 1 | SRIF-2 | SS1-R | Somatostatin SRIF2A (SS1R) receptor | G-protein coupled receptor | SSR1_HUMAN | Sst1 | SS1R | somatostatin receptor 1 | Somatostatin receptor type 1 | SST1 | SS-1-R

SSTR1: A Potential Drug Target and Biomarker for Various Diseases

Somatostatin receptor 1 (SSTR1) is a transmembrane protein that is expressed in various tissues throughout the body. It plays a critical role in regulating cellular processes such as cell growth, differentiation, and survival. SSTR1 has also been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SSTR1 is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a wide range of functions in various physiological processes. GPCR family members are involved in a variety of cellular processes, including signaling pathways, ion channels, and neurotransmitter signaling.

SSTR1 is expressed in various tissues throughout the body, including the brain, pancreas, heart, kidneys, and gastrointestinal tract. It has been shown to be involved in the regulation of cellular processes such as cell growth, differentiation, and survival. SSTR1 has also has been shown to play a role in the regulation of various signaling pathways, including the Wnt pathway, which is involved in the regulation of cell growth and differentiation.

SSTR1 has also been identified as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that inhibiting SSTR1 can lead to the growth inhibition and apoptosis of cancer cells. Additionally, SSTR1 has been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In these conditions, the function of SSTR1 has been shown to be impaired, which could be a potential target for therapeutic intervention.

In addition to its potential therapeutic applications, SSTR1 has also been identified as a potential biomarker for various diseases. For example, studies have shown that the expression of SSTR1 is decreased in various tissues and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that SSTR1 may be a useful biomarker for these conditions. Additionally, SSTR1 has been shown to be involved in the regulation of various physiological processes, including cell growth, differentiation, and survival, which could be useful for the development of new diagnostic tests for these conditions.

In conclusion, SSTR1 is a transmembrane protein that is involved in the regulation of various cellular processes throughout the body. Its function has been shown to be important in the regulation of cell growth, differentiation, and survival. As a potential drug target and biomarker, SSTR1 has the potential to be a useful therapeutic intervention for various diseases. Further research is needed to fully understand the role of SSTR1 in these conditions and to develop new treatments based on its properties.

Protein Name: Somatostatin Receptor 1

Functions: Receptor for somatostatin with higher affinity for somatostatin-14 than -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins

The "SSTR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SSTR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets